Naoko Hata Sugi

Selective degradation of splicing factor CAPERα by anticancer sulfonamides

Taisuke Uehara, Yukinori Minoshima, Koji Sagane et al. · Nature Chemical Biology · 2017 · 366 citations

Medicinal Chemistry, Medicine, Natural Sciences +6

Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle

Takashi Owa, Hiroshi Yoshino, Tatsuo Okauchi et al. · Journal of Medicinal Chemistry · 1999 · 323 citations

Tumor Biology, Medicinal Chemistry, Drug Targeting +15

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

Kiyoshi Okamoto, Kotaro Kodama, Kazuma Takase et al. · Cancer Letters · 2013 · 282 citations · Full text

Cancer Biology, Tumor Biology, Oncology +17

Biological validation that SF3b is a target of the antitumor macrolide pladienolide

Akira Yokoi, Yoshihiko Kotake, Kentaro Takahashi et al. · FEBS Journal · 2011 · 178 citations · Full text

Widr Cells, Tumor Biology, Oncology +14

E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo

Yoichi Ozawa, Naoko Hata Sugi, Takeshi Nagasu et al. · European Journal of Cancer · 2001 · 132 citations

Medicinal Chemistry, Pharmaceutical Chemistry, Pharmaceutical Science +10